WHO Launches Initiative to Develop RNA Vaccines for H5N1 Bird Flu

The project aims to boost vaccine production capacity in low- and middle-income countries, led by Argentina's Sinergium Biotech.

The initiative is part of the WHO and Medicines Patent Pool's mRNA Technology Transfer Programme.
Sinergium Biotech will conduct preclinical tests and share findings with global partners.
The goal is to enhance pandemic preparedness and ensure equitable vaccine access.
The project responds to the rising threat of H5N1, which has seen increased outbreaks in birds and mammals.
mRNA technology allows for rapid adaptation to produce various vaccines and therapeutics.